April 25, 2019 10:22 AM EDT

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration

Natalie Grover

Reporter

→ About two years after Biogen $BIIB walked away from Mitsubishi Tanabe Pharma‘s MT-1303 (amiselimod), the Japanese drugmaker has joined forces with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

What Trump's CMS can and can't change with the second round of drug price negotiations

Updated: J&J to buy Intra-Cellular for $14.6B in latest neuroscience bet

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Af­ter Bio­gen ex­it, Mit­subishi Tan­abe Phar­ma links up with Sal­ix to de­vel­op amise­limod; Two drug de­vel­op­ers set up an­tibi­ot­ic col­lab­o­ra­tion

Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration